SEC Form 4 · accession 0001209191-17-039234
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Fust
Director
Period of report
Jun 8, 2017
Accepted (ET)
Jun 12, 2017 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 8, 2017 | A | 5,000 | $0.00 | A | 27,298 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F2 | $13.20 | Jun 8, 2017 | A | 21,500 | A | — | Jun 8, 2024 | Common Stock | 21,500 | 21,500 | D |
Explanation of responses
- F1These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service.
- F2The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service.